|Bid||0.000 x 0|
|Ask||0.000 x 0|
|Day's range||32.164 - 33.900|
|52-week range||24.450 - 55.950|
|PE ratio (TTM)||N/A|
|Earnings date||24 Apr 2018 - 30 Apr 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||47.64|
But what is clear is that in the not too distant future, PCSK9 inhibitors will be priced in a way that will be palatable to payers thereby making this class of important drugs available to those whose lives can be saved or prolonged by them.
The Medicines Company today announced that it will participate in the Oppenheimer 28th Annual Healthcare Conference on Tuesday, March 20, 2018, in New York City, NY. The Company is scheduled to present at 08:00 a.m., Eastern Time.
Esperion popped Monday after a study from Regeneron and Sanofi validated the long-term benefits of lowering LDL cholesterol.
Alnylam Pharmaceuticals (ALNY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The Medicines Company today announced that randomization of more than 1,500 patients in the ORION-10 trial in the United States has been completed in only 12 weeks – considerably beating its goal of 22 weeks.
The Medicines Company today announced that it will participate in the Cowen 38th Annual Health Care Conference on Tuesday, March 13, 2018, in Boston, MA. The Company is scheduled to present at 10:00 a.m., Eastern Time.
Medicines Company said in a regulatory filing it was restructuring its board by reducing the number of members to 7 from 12. The company said it would nominate Denner, along with Fredric Eshelman, Geno Germano, John Kelly, Clive Meanwell, Paris Panayiotopoulos and Sarah J. Schlesinger to the board.
Medicines Company shares surged 6.2% in heavy morning trade on Thursday after the company reported plans to restructure its board and reduce the number of board members from 12 to seven in a financial ...
The Medicines Company today announced that its Board of Directors has appointed Dr. Sarah Schlesinger as a new, independent Director of the Company, effective immediately.
Medicines Company (MDCO) incurs wider-than-expected loss in the fourth quarter of 2017. Moreover, the top line declines year over year on low Angiomax sales.
The Parsippany, New Jersey-based company said it had a loss of $2.45 per share. Losses, adjusted to account for discontinued operations, came to $2.19 per share. The results missed Wall Street expectations. ...
The Medicines Company today reported its financial results for the fourth quarter and full year ended December 31, 2017.
The Medicines Company today announced that the target of 400 patients randomized in the ORION-9 trial has been exceeded in 10 weeks – considerably ahead of its anticipated recruitment goal of 24 weeks.
The Medicines Company will host a conference call and webcast on Wednesday, February 21, 2018, at 8:30 a.m., Eastern Time, to discuss fourth-quarter and full-year 2017 financial results and operational developments.
The Medicines Company today announced that it will participate in the Leerink Partners 7th Annual Global Healthcare Conference on Wednesday, February 14, 2018, in New York City.
The end of the third sentence of the first paragraph of the release should read: then followed to the end of the study at 540 days ).
Investors in Medicines Company (MDCO) need to pay close attention to the stock based on moves in the options market lately.